Targeted Treatment for Advanced Non-Small Cell Lung Cancer that Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab hyaluronidase works in treating patients with MET amplification non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Amivantamab hyaluronidase is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab hyaluronidase may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Inclusion Criteria
- Participants must have been assigned to S1900J by the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC). Assignment to S1900J is determined by documentation of NSCLC with MET amplification in the LUNGMAP study
- Participants must have MET amplification identified through on-study testing of tumor or have documentation of MET amplification from a previously completed tissue or blood based next-generation sequencing (NGS) test
- Participants must have measurable disease documented by CT or MRI. The CT from a combined positron emission tomography (PET)/CT may be used to document measurable disease ONLY if it is of diagnostic quality: otherwise, it may be used to document non-measurable disease only. Measurable disease must be assessed within 28 days prior to sub-study registration. Pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease. Non-measurable disease must be assessed within 42 days prior to sub-study registration. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form. Participants whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to sub-study registration to be considered measurable
- Participants must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to sub-study registration
- Participants with asymptomatic CNS metastasis (brain metastases or leptomeningeal disease) must be clinically stable and asymptomatic for at least 14 days prior to sub-study registration * NOTE: Participants can be on a low-dose corticosteroid treatment (≤ 10 mg prednisone or equivalent) for at least 14 days prior to study treatment
- Participants must not have other known actionable oncogenic alterations, such as (but not limited to) EGFR sensitizing mutations, EGFR T790M mutation, MET Exon-14 skipping mutant NSCLC, ALK gene fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, HER2 mutation, KRAS G12C, and BRAF V600E mutation
- Participants must have progressed (in the opinion of the treating physician) following the most recent line of therapy
- Participants must have received at least one line of systemic treatment for Stage IV or recurrent NSCLC
- Participants must have recovered (≤ Grade 1) from any side effects of prior therapy. The exception is if a side effect from a prior treatment is known to be permanent without expected further recovery or resolution (i.e., endocrinopathy from immunotherapy or cisplatin neurotoxicity)
- Participants must not have been previously treated for any cancer with MET tyrosine kinase inhibitors (TKIs) such as tepotinib, capmatinib, and crizotinib
- Participants must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to sub-study registration
- Participants must not have a prior treatment with anti-PD-1 or anti-PD-L1 antibody within 6 weeks of sub-study registration
- Participants must not have received any radiation therapy within 14 days prior to sub-study registration
- Participants must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study
- Participants must not have had major surgery excluding placement of vascular access or tumor biopsy, or had significant traumatic injury within 28 days prior to sub-study registration, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study * NOTE: Participants with planned surgical procedures to be conducted under local anesthesia may participate
- Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen
- Absolute neutrophil count ≥ 1.5 x 10^3/uL (within 28 days prior to sub-study registration)
- Hemoglobin >= 10.0 g/dL (within 28 days prior to sub-study registration)
- Platelets ≥ 75 x 10^3/uL (within 28 days prior to sub-study registration)
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) unless history of Gilbert’s disease. Participants with history of Gilbert’s disease must have total bilirubin ≤ 5 x institutional ULN (within 28 days prior to sub-study registration)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × institutional ULN. Participants with history of liver metastasis must have AST and ALT ≤ 5 x ULN (within 28 days prior to sub-study registration)
- Participants must have a serum creatinine ≤ the institutional upper limit of normal (IULN) or calculated creatinine clearance ≥ 45 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to sub-study registration. For creatinine clearance formula see the tools on the CRA Workbench
- Participants’ most recent Zubrod performance status must be 0-2 and be documented within 28 days prior to sub-study registration
- Participants must have a completed medical history and physical exam within 28 days prior to sub-study registration
- Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better
- Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy and have undetectable viral load test on the most recent test results obtained within 6 months prior to sub-study registration
- Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to sub-study registration
- Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to sub-study registration
- Participants with known diabetes as determined by the treating investigator must show evidence of controlled disease within 14 days prior to sub-study registration
- Participants of reproductive potential must have a negative serum pregnancy test within 7 days prior to sub-study registration
- Participants must not have other clinically active infectious liver disease
- Participants must not have clinically significant hypertension within 28 days prior to sub-study registration as determined by the treating investigator
- Participants must not have a history of pneumonitis that required drug therapy or an active symptomatic interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis
- Participants who had an infection that required antimicrobial therapy (to clear the infection) prior to S1900J registration, must be planning to complete the antibiotics within 7 days prior to starting treatment on S1900J
- Participants must not have active bleeding diathesis as determined by the treating investigator
- Participants must not have impaired oxygenation requiring continuous oxygen supplementation as determined by the treating investigator
- Participants must not have psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements as determined by the treating investigator
- Participants must not have any ophthalmologic condition that is unstable in the opinion of the treating investigator
- Participants must not be pregnant or breastfeeding (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
- Participants must agree to have blood specimens submitted for circulating tumor deoxyribonucleic acid (DNA) (ctDNA)
- Participants must also be offered participation in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System
- Participants who provided documentation of MET amplification in LUNGMAP from a previously completed non-FMI test must agree to submit archival tissue (if available) for retrospective FMI testing
- Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines * NOTE: Participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
Additional locations may be listed on ClinicalTrials.gov for NCT06116682.
Locations matching your search criteria
United States
Arkansas
Jonesboro
Little Rock
California
Auburn
Berkeley
Fremont
La Jolla
Loma Linda
Modesto
Palo Alto
Rancho Mirage
Roseville
Sacramento
San Francisco
San Mateo
Santa Rosa
Sunnyvale
Vallejo
Colorado
Aurora
Colorado Springs
Fort Collins
Greeley
Loveland
Delaware
Dover
Milford
Florida
Gainesville
Georgia
Gainesville
Hawaii
Aiea
Ewa Beach
Honolulu
Idaho
Boise
Caldwell
Coeur D'Alene
Nampa
Post Falls
Sandpoint
Illinois
Aurora
Barrington
Bloomington
Canton
Carthage
Chicago
Crystal Lake
Danville
Decatur
Downers Grove
Effingham
Elgin
Eureka
Galesburg
Hazel Crest
Hines
Kewanee
Libertyville
Macomb
Mattoon
Maywood
Mount Vernon
O'Fallon
Oak Lawn
Ottawa
Palos Heights
Park Ridge
Pekin
Peoria
Peru
Princeton
Springfield
Urbana
Washington
Indiana
Indianapolis
Iowa
Ames
Boone
Fort Dodge
Jefferson
Marshalltown
Kansas
Fairway
Hays
Kansas City
Lawrence
Olathe
Overland Park
Salina
Topeka
Westwood
Kentucky
Lexington
Maine
Brewer
Massachusetts
Burlington
Peabody
Springfield
Worcester
Michigan
Ann Arbor
Brighton
Canton
Chelsea
Detroit
Flint
Lansing
Livonia
Pontiac
Ypsilanti
Minnesota
Deer River
Duluth
Hibbing
Sandstone
Virginia
Mississippi
Columbus
Grenada
New Albany
Oxford
Southhaven
Missouri
Cape Girardeau
Farmington
Kansas City
Lee's Summit
Saint Louis
Sainte Genevieve
Sullivan
Sunset Hills
Montana
Anaconda
Billings
Bozeman
Great Falls
Kalispell
Missoula
Nevada
Henderson
Las Vegas
New Hampshire
Concord
Manchester
New Jersey
Moorestown
Voorhees
Ohio
Columbus
Sylvania
Oklahoma
Lawton
Oklahoma City
Oregon
Newberg
Ontario
Oregon City
Portland
Pennsylvania
Chambersburg
Danville
Dickson City
Ephrata
Gettysburg
Lebanon
Lewisburg
Scranton
Wilkes-Barre
York
South Carolina
Charleston
Tennessee
Collierville
Memphis
Utah
Salt Lake City
Virginia
Charlottesville
Washington
Edmonds
Issaquah
Seattle
West Virginia
Huntington
Morgantown
Wisconsin
Ashland
Burlington
Cudahy
Germantown
Grafton
Green Bay
Kenosha
La Crosse
Marinette
Milwaukee
Oshkosh
Racine
Sheboygan
Summit
Two Rivers
Wauwatosa
West Allis
PRIMARY OBJECTIVE:
I. To evaluate the objective response rate (ORR) (confirmed and unconfirmed, complete and partial) in participants with MET amplification-positive non-small cell lung cancer (NSCLC) treated with amivantamab and recombinant human hyaluronidase (amivantamab hyaluronidase) within each cohort.
SECONDARY OBJECTIVES:
I. To evaluate the response rates within each cohort among the participants with MET amplification by FoundationOne CDx or FoundationOne Liquid CDx.
II. To evaluate progression-free survival (PFS) within each cohort.
III. To evaluate overall survival (OS) within each cohort.
IV. To evaluate the duration of response among responders within each cohort.
V. To evaluate the frequency and severity of toxicities within each cohort and combined across all study participants.
TRANSLATIONAL MEDICINE OBJECTIVES:
I. To evaluate the frequency of MET amplifications detected among tissue samples submitted for participants with MET amplification-positive NSCLC using a test other than FoundationOne CDx or FoundationOne Liquid CDx for participation in the LUNGMAP protocol.
II. To collect, process, and bank cell-free deoxyribonucleic acid (cfDNA) prior to treatment on cycle 1 day 1, cycle 3 day 1, and at first progression for future development of a proposal to evaluate comprehensive next-generation sequencing of circulating tumor deoxyribonucleic acid (ctDNA).
III. To establish a tissue/blood repository from participants with refractory non-small cell lung cancer (NSCLC).
OUTLINE:
Patients receive amivantamab hyaluronidase subcutaneously (SC) on days 1, 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computerized tomography (CT) or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up for up to 3 years.
Trial PhasePhase II
Trial Typetreatment
Lead OrganizationSWOG
Principal InvestigatorChristian Diego Rolfo
- Primary IDS1900J
- Secondary IDsNCI-2023-07072
- ClinicalTrials.gov IDNCT06116682